Page 2 - Michael Klichinsky News Today

Carisma Therapeutics (NASDAQ:CARM – Get Rating) was upgraded by stock analysts at Jefferies Financial Group from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Marketbeat reports. The brokerage presently has a $7.00 price objective on the stock. Jefferies Financial Group’s price target would indicate a potential upside of […]

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and...

HC Wainwright reissued their buy rating on shares of Carisma Therapeutics (NASDAQ:CARM – Get Rating) in a research note released on Wednesday morning, Marketbeat.com reports. They currently have a $10.00 target price on the stock. HC Wainwright also issued estimates for Carisma Therapeutics’ Q2 2023 earnings at ($0.66) EPS, Q3 2023 earnings at ($0.71) EPS, […]

Carisma Therapeutics (NASDAQ:CARM – Get Rating) and Synaptogenix (NASDAQ:SNPX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, valuation, earnings, analyst recommendations, institutional ownership and profitability. Valuation & Earnings This table compares Carisma Therapeutics and Synaptogenix’s […]

Carisma Therapeutics (NASDAQ:CARM – Get Rating) will be posting its quarterly earnings results on Friday, May 12th. Carisma Therapeutics Stock Up 2.7 % Shares of CARM stock traded up $0.16 on Thursday, hitting $6.02. 84,394 shares of the stock were exchanged, compared to its average volume of 117,782. The company has a market capitalization of […]

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"), a clinical stage biopharmaceutical company focused on discovering and developing...

PHILADELPHIA, April 6, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced... | April 6, 2023

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM), a clinical stage biopharmaceutical company focused on discovering and developing innovative...

Carisma Therapeutics, Inc. (NASDAQ:CARM – Get Rating)’s share price traded up 0.3% during trading on Friday . The stock traded as high as $3.20 and last traded at $3.10. 40,007 shares were traded during mid-day trading, a decline of 56% from the average session volume of 90,607 shares. The stock had previously closed at $3.09. […]

19.01.2023 - Sesen Bio, Inc. (Nasdaq: SESN) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Carisma Therapeutics Inc. (Carisma), a privately held, ...